亚胺培南/西司他丁联合奈替米星对甲氧西林耐药金葡球菌感染小鼠败血症体内协同抗菌作用研究

Synergistic Activity of Tienam and Netilmycin in a Combination Therapy in Experimental MRSA Infection of Mice

目的：评价亚胺培南／西司他丁联合奈替米星对甲氧西林耐药金黄色葡萄球菌感染小鼠模型的体内保护作用。方法： ０．５ｍｌ １Ｍ ＬＤ菌量甲氧西林耐药金黄色葡萄球菌感染小鼠，然后皮下给０．２ｍｌ的亚胺培南／西司他丁联合奈替米星药液。结果：亚胺培南／西司他丁联合奈替米星对ＭＲＳＡ９８－１５、ＭＲＳＡ９８－１７感染小鼠的半数有效量ＥＤ５０值分别为１６．３９和１０．６２ｍｇ·ｋｇ－１，均显著低于亚胺培南／西司他丁（３８．０３，２２．０１ ｍｇ·ｋｇ－１）与奈替米星（４３．１６， ２５．５９ ｍｇ·ｋｇ－１）单独用药量（０．０１＜Ｐ＜０．０５）。结论：亚胺培南／西司他丁联合奈替米星在体内的协同抗菌活性优于亚胺培南／西司他丁与奈替米星两药单独治疗作用。

OBJECTIVE: The study is to evaluate the synergistic antibacterial activity of tienam and netilmycin in experimental methicilin-resistant staphylococcus aureus infection in mice. METHODS: The mice were challenged ip with 0.5 ml 1MLD methicillin-resistant staphylococcus aureus. Tienam combined with netilmycin were administered subcutaneously after infection. RESULTS: The result showed that the ED50S of the combination of tienam and netilmycin in the treatment of MRSA 98-15 and 98-17 infections were 16.39 and 10.62mg.kg-1 respectively. Both were significantly lower than those of tienam (38.03, 22.01mg.kg-1) and netimycin (43.16, 25.59 mg.kg-1) alone (0.01<P<0.05). CONCLUSION: The combination of tienam with netilmycin in the treatment of infection caused by MRSA in mice possessed a synergism, which is worth of further investigations.